This invention relates to compounds, compositions, and methods useful for
modulating interleukin and/or interleukin receptor gene expression using
short interfering nucleic acid (siNA) molecules. This invention also
relates to compounds, compositions, and methods useful for modulating the
expression and activity of other genes involved in pathways of
interleukin and/or interleukin receptor gene expression and/or activity
by RNA interference (RNAi) using small nucleic acid molecules. In
particular, the instant invention features small nucleic acid molecules,
such as short interfering nucleic acid (siNA), short interfering RNA
(siRNA), double-stranded RNA (dsRNA), micro-RNA (mRNA), and short hairpin
RNA (shRNA) molecules and methods used to modulate the expression of
interleukin and/or interleukin receptor genes, such as IL-1, IL-2, IL-3,
IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14,
IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24,
IL-25, IL-26, and IL-27 genes and IL-1R, IL-2R, IL-3R, IL-4R, IL-5R,
IL-6R, IL-7R, IL-8R, IL-9R, IL-10R, IL-11R, IL-12R, IL-13R, IL-14R,
IL-15R, IL-16R, IL-17R, IL-18R, IL-19R, IL-20R, IL-21R, IL-22R, IL-23R,
IL-24R, IL-25R, IL-26R, and IL-27R. Such small nucleic acid molecules are
useful, for example, for treating, preventing, inhibiting, or reducing
cancer, inflammatory, respiratory, autoimmune, cardiovascular,
neurological, and/or proliferative diseases, disorders, or conditions in
a subject or organism, and for any other disease, trait, or condition
that is related to or will respond to the levels of interleukin and/or
interleukin receptor in a cell or tissue, alone or in combination with
other treatments or therapies.
